Startup HiberCell gets more than $60M to focus on mechanism behind cancer metastasis, recurrence
The New York-based company has two programs in preclinical discovery, based on research conducted at Mount Sinai's Tisch Cancer Institute.
The New York-based company has two programs in preclinical discovery, based on research conducted at Mount Sinai's Tisch Cancer Institute.
The company will focus on what it called a previously unexplored field in drug discovery, membrane-less cell organelles called biomolecular condensates
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Estimates of the incidence of FSHD, which has two types, range from 1-in-20,000 to 1-in-8,333, or about 870,000 cases worldwide.